NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued materially misleading business information to the investing public. So What: If you purchased Soleno Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through
Related Questions
What is the likelihood and timeline of the securities class action investigation resulting in a material settlement or judgment?
How might this news affect Soleno Therapeutics' short‑term stock volatility and trading volume?
Are there any potential catalysts or upcoming corporate events that could mitigate or exacerbate the impact of the investigation on the company's valuation?